Combination treatment with cetuximab in advanced nasopharyngeal carcinoma patients: a meta-analysis

References

• QiuWZPengXSXiaHQHuangPYGuoXCaoKJA retrospective study comparing the outcomes and toxicities of intensity-modulated radiotherapy versus two-dimensional conventional radiotherapy for the treatment of children and adolescent nasopharyngeal carcinomaJ Cancer Res Clin Oncol20171431563157210.1007/s00432-017-2401-y28342002
   PubMed Web of Science ®Google Scholar
• RenGDuLMaLClinical observation of 73 nasopharyngeal carcinoma patients treated by helical tomotherapy: the China experienceTechnol Cancer Res Treat20111025926610.7785/tcrt.2012.50020121517132
   PubMed Web of Science ®Google Scholar
• YangQZouXYouRProposal for a new risk classification system for nasopharyngeal carcinoma patients with post-radiation nasopharyngeal necrosisOral Oncol201767838810.1016/j.oraloncology.2017.02.01228351585
   PubMed Web of Science ®Google Scholar
• LinJLvXNiuMRadiation-induced abnormal cortical thickness in patients with nasopharyngeal carcinoma after radiotherapyNeuroimage Clin20171461062110.1016/j.nicl.2017.02.02528348952
   PubMed Web of Science ®Google Scholar
• ForastiereAAChemotherapy in the treatment of locally advanced head and neck cancerJ Surg Oncol20089770170710.1002/jso.2101218493921
   PubMed Web of Science ®Google Scholar
• OuYangPYZhangLNXiaoYValidation of published nomograms and accordingly individualized induction chemotherapy in nasopharyngeal carcinomaOral Oncol201767374510.1016/j.oraloncology.2017.01.00928351579
   PubMed Web of Science ®Google Scholar
• KoukourakisMITsoutsouPGKarpouzisARadiochemotherapy with cetuximab, cisplatin, and amifostine for locally advanced head and neck cancer: a feasibility studyInt J Radiat Oncol Biol Phys20107791510.1016/j.ijrobp.2009.04.06019744802
   PubMed Web of Science ®Google Scholar
• YangESMurphyBMChungCHEvolution of clinical trials in head and neck cancerCrit Rev Oncol Hematol200971294210.1016/j.critrevonc.2008.09.01518996026
   PubMed Web of Science ®Google Scholar
• RazakARSiuLLLeTCMolecular targeted therapies in all histologies of head and neck cancers: an updateCurr Opin Oncol20102221222010.1097/CCO.0b013e328338001f20173639
   PubMed Web of Science ®Google Scholar
• ChanSLMaBBNovel systemic therapeutic for nasopharyngeal carcinomaExpert Opin Ther Targets201216Suppl 1S63S6810.1517/14728222.2011.63564622313344
   PubMedGoogle Scholar
• WardMCReddyCAAdelsteinDJKoyfmanSAUse of systemic therapy with definitive radiotherapy for elderly patients with head and neck cancer: a National Cancer Data Base analysisCancer201610.1002/cncr.30214
   Google Scholar
• MaXHuangJWuXEpidermal growth factor receptor could play a prognostic role to predict the outcome of nasopharyngeal carcinoma: A meta-analysisCancer Biomark20141426727710.3233/CBM-14040124934370
   PubMed Web of Science ®Google Scholar
• SunWLongGWangJMeiQLiuDHuGPrognostic role of epidermal growth factor receptor in nasopharyngeal carcinoma: a meta-analysisHead Neck2014361508151610.1002/hed.2348123996630
   PubMed Web of Science ®Google Scholar
• MaBBPoonTCToKFPrognostic significance of tumor angiogenesis, Ki 67, p53 oncoprotein, epidermal growth factor receptor and HER2 receptor protein expression in undifferentiated nasopharyngeal carcinoma–a prospective studyHead Neck20032586487210.1002/hed.1030712966511
   PubMed Web of Science ®Google Scholar
• CaoXJHaoJFYangXHPrognostic value of expression of EGFR and nm23 for locoregionally advanced nasopharyngeal carcinomaMed Oncol20122926327110.1007/s12032-010-9782-y21221850
   PubMed Web of Science ®Google Scholar
• ZhangPWuSKWangYp53, MDM2, eIF4E and EGFR expression in nasopharyngeal carcinoma and their correlation with clinicopathological characteristics and prognosis: A retrospective studyOncol Lett2015911311810.3892/ol.2014.263125435943
   PubMed Web of Science ®Google Scholar
• YuanCXuXHChenZCombination treatment with antiEGFR monoclonal antibodies in advanced nasopharyngeal carcinoma: a meta-analysisJ BUON2015201510151726854448
   PubMed Web of Science ®Google Scholar
• MaBBKamMKLeungSFA phase II study of concurrent cetuximab-cisplatin and intensity-modulated radiotherapy in locoregionally advanced nasopharyngeal carcinomaAnn Oncol2012231287129210.1093/annonc/mdr40121948811
   PubMed Web of Science ®Google Scholar
• ZhangXDuLZhaoFWangQYangSMaLA phase II clinical trial of concurrent helical tomotherapy plus cetuximab followed by adjuvant chemotherapy with cisplatin and docetaxel for locally advanced nasopharyngeal carcinomaInt J Biol Sci20161244645310.7150/ijbs.1293727019628
   PubMed Web of Science ®Google Scholar
• HeXXuJGuoWJiangXWangXZongDCetuximab in combination with chemoradiation after induction chemotherapy of locoregionally advanced nasopharyngeal carcinoma: preliminary resultsFuture Oncol201391459146710.2217/fon.13.15124106897
   PubMed Web of Science ®Google Scholar
• XuTOuXShenCHuCCetuximab in combination with chemoradiotherapy in the treatment of recurrent and/or metastatic nasopharyngeal carcinomaAnticancer Drugs201627667010.1097/CAD.000000000000029426352217
   PubMed Web of Science ®Google Scholar
• RiazNShermanEKoutcherLConcurrent chemoradiotherapy with cisplatin versus cetuximab for squamous cell carcinoma of the head and neckAm J Clin Oncol201639273110.1097/COC.000000000000000624401670
   PubMed Web of Science ®Google Scholar
• ShapiroLQShermanEJRiazNEfficacy of concurrent cetuximab vs. 5-fluorouracil/carboplatin or high-dose cisplatin with intensity-modulated radiation therapy (IMRT) for locally-advanced head and neck cancer (LAHNSCC)Oral Oncol20145094795510.1016/j.oraloncology.2014.07.00125132089
   PubMed Web of Science ®Google Scholar
• NiuXHuCKongLExperience with combination of cetuximab plus intensity-modulated radiotherapy with or without chemotherapy for locoregionally advanced nasopharyngeal carcinomaJ Cancer Res Clin Oncol20131391063107110.1007/s00432-013-1419-z23525586
   PubMed Web of Science ®Google Scholar
• LicitraLBossiPLocatiLDBergaminiCIs restoring platinum sensitivity the best goal for cetuximab in recurrent/metastatic nasopharyngeal cancer?J Clin Oncol20052377577759 author reply 7758–775910.1200/JCO.2005.02.785416234549
   PubMed Web of Science ®Google Scholar
• ChanATHsuMMGohBCMulticenter, phase II study of cetuximab in combination with carboplatin in patients with recurrent or metastatic nasopharyngeal carcinomaJ Clin Oncol2005233568357610.1200/JCO.2005.02.14715809453
   PubMed Web of Science ®Google Scholar
• SuntharalingamMKwokYGoloubevaOPhase II study evaluating the addition of cetuximab to the concurrent delivery of weekly carboplatin, paclitaxel, and daily radiotherapy for patients with locally advanced squamous cell carcinomas of the head and neckInt J Radiat Oncol Biol Phys2012821845185021601372
   PubMed Web of Science ®Google Scholar
• JensenADKraussJPotthoffKPhase II study of induction chemotherapy with TPF followed by radioimmunotherapy with Cetuximab and intensity-modulated radiotherapy (IMRT) in combination with a carbon ion boost for locally advanced tumours of the oro-, hypopharynx and larynx–TPF-C-HITBMC Cancer20111118210.1186/1471-2407-11-18221595970
   PubMed Web of Science ®Google Scholar
• YoshinoTHasegawaYTakahashiSPlatinum-based chemotherapy plus cetuximab for the first-line treatment of Japanese patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck: results of a phase II trialJpn J Clin Oncol20134352453110.1093/jjco/hyt03423479384
   PubMed Web of Science ®Google Scholar
• RiazNShermanEJFuryMLeeNShould cetuximab replace Cisplatin for definitive chemoradiotherapy in locally advanced head and neck cancerJ Clin Oncol20133128728810.1200/JCO.2012.46.904923213096
   PubMed Web of Science ®Google Scholar
• BibaultJEMorelleMPerrierLToxicity and efficacy of cetuximab associated with several modalities of IMRT for locally advanced head and neck cancerCancer Radiother20162035736110.1016/j.canrad.2016.05.00927345843
   PubMed Web of Science ®Google Scholar
• FengHXGuoSPLiGRToxicity of concurrent chemoradio-therapy with cetuximab for locoregionally advanced nasopharyngeal carcinomaMed Oncol20143117010.1007/s12032-014-0374-025119503
   PubMed Web of Science ®Google Scholar
• PageMJMoherDEvaluations of the uptake and impact of the Preferred Reporting Items for Systematic reviews and Meta-Analyses (PRISMA) Statement and extensions: a scoping reviewSyst Rev2017626310.1186/s13643-017-0663-829258593
   PubMed Web of Science ®Google Scholar
• WuXHuangJLiuLCetuximab concurrent with IMRT versus cisplatin concurrent with IMRT in locally advanced nasopharyngeal carcinoma: A retrospective matched case-control studyMedicine (Baltimore)20169539e492610.1097/MD.000000000000486427684830
   PubMed Web of Science ®Google Scholar
• XiaW-XLiangHLvXCombining cetuximab with chemoradiotherapy in patients with locally advanced nasopharyngeal carcinoma: a propensity score analysisOral Oncol20176716717410.1016/j.oraloncology.2017.02.02628351572
   PubMed Web of Science ®Google Scholar
• XuTLiuYDouSLiFGuanXZhuGWeekly cetuximab concurrent with IMRT aggravated radiation-induced oral mucositis in locally advanced nasopharyngeal carcinoma: results of a randomized phase II studyOral Oncol20155187587910.1016/j.oraloncology.2015.06.00826163437
   PubMed Web of Science ®Google Scholar
• ZhouXSThe effect of cetuximab combined with radiotherapy in the treatment of advanced nasopharyngeal carcinomaJ North Pharm20171454243 Chinese
   Google Scholar
• YouRHuaYJLiuYPConcurrent chemoradiotherapy with or without anti-EGFR-targeted treatment for stage II–IVb nasopharyngeal carcinoma: retrospective analysis with a large cohort and long follow-upTheranostics201772314232410.7150/thno.1971028740554
   PubMed Web of Science ®Google Scholar
• WangXXClinical asesment of the radiotherapy and chemotherapy combined with cetuximab in the treatment of nasopharyngeal carcinomaJ Clin Otorhinolaryngol Head Neck Surg2016301512291231 Chinese
   Google Scholar
• SunJHLiJClinical efficacy of rituximab combined with chemotherapy in the treatment of patients with locally avanced nasopharyngeal carcinomaChina J Pharm Econ201679092 Chinese
   Google Scholar
• ZengTZhangYLLiJJAnalysis of the efficacy of cetuximab combined with chemotherapy and radiotherapy in the treatment of advanced nasopharyngeal carcinomaChin J Front Med Sci2016844548 Chinese
   Google Scholar
• CaoXQLiaoYClinical study of cetuximab combined with radiotherapy on patients with advanced nasopharyngeal carcinomaChin J Clin Pharmacol2016322120122 Chinese
   Google Scholar
• LiYChenQYTangLQConcurrent chemoradiotherapy with or without cetuximab for stage II to IVb nasopharyngeal carcinoma: a case-control studyBMC Cancer20171756710.1186/s12885-017-3552-628836950
   PubMed Web of Science ®Google Scholar
• YangZYWanHChenCXYuanHWangPLiuJStudy on the efficacy of cetuximab in combination with cisplatin chemotherapy and intensity modulated radiotherapy in treatment of patients with nasopharyngeal carcinomaJ Clin Exp Med20161514548 Chinese
   Google Scholar
• FuMHThe effect of cetuximab combined with chemoradiotherapy on prognosis of patients with advanced nasopharyngeal carcinomaAnti Infect Pharm2015121121122 Chinese
   Google Scholar
• ZhaoZQOuYangXNYuZYLiJWangHYinLHCurative effects of cetuximab combined with intensity modulated radiation therapy and concurrent chemotherapy on advanced nasopharyngeal carcinomaMed J Nation Defening Forces Southwest China2015257750753 Chinese
   Google Scholar
• YaoXQYangCLYangGYangYBThe effect of cetuximab combined with gemcitabine in the treatment of the advanced nasopharyngeal carcinoma followed by PaclitaxelAnhui Med Pharm J201519713911392 Chinese
   Google Scholar
• WangDXClinical analysis of cetuximab combined with chemoradiotherapy for advanced nasopharyngeal carcinomaMod Diagn Treat2015261124652466 Chinese
   Google Scholar
• YouRSunRHuaYJCetuximab or nimotuzumab plus intensity-modulated radiotherapy versus cisplatin plus intensity-modulated radiotherapy for stage II-IVb nasopharyngeal carcinomaInt J Cancer20171411265127610.1002/ijc.3081928577306
   PubMed Web of Science ®Google Scholar
• ZhouLSThe curative effect of cetuximab combined with chemoradiotherapy for 63 patients with advanced nasopharyngeal carcinomaChina Prac Med2013831131132 Chinese
   Google Scholar
• ZhengZHLiSELuoWJAnalysis on the curative effect of cetuximab combined with concurrent cisplatin chemotherapy and intensity modulated radiation therapy for locally advanced nasopharyngeal carcinomaChina Foreign Med Treat20133434 Chinese
   Google Scholar
• TangDHZhangYXCaiJThe clinical efficacy of cetuximab combined with radiotherapy and chemotherapy in the treatment of locally advanced nasopharyngeal carcinomaAnti-Tumor Pharm201332119121+129 Chinese
   Google Scholar
• FuXLMengMSChenXFLiYXWuWYRT combined with cetuximab in treating advanced nasopharyngeal carcinomaChina Pharm201524184143 Chinese
   Google Scholar
• WuCZCurative effects of cetuximab combined with concurrent chemo-and radiotherapy on recurrent nasopharyngeal carcinomaMed J Nation Defening Forces Southwest China2013235509512 Chinese
   Google Scholar
• GaoHBZhengDYThe application of cetuximab in patients with local advanced nasopharyngeal carcinomaGuangdong Med J2013341422442246 Chinese
   Google Scholar
• PengZYZhengFBWenHClinical efficacy of cetuximab combined with IMRT in treatment of patients with locally advanced nasopharyngeal carcinomaChin J Clin Oncol Rehabil2013209993995 Chinese
   Google Scholar
• ChenWZhengRBaadePDCancer statistics in China, 2015CA Cancer J Clin20166611513210.3322/caac.2133826808342
   PubMed Web of Science ®Google Scholar
• LiZZLiYYYanSPNimotuzumab combined with concurrent chemoradiotherapy benefits patients with advanced nasopharyngeal carcinomaOnco Targets Ther2017105445545810.2147/OTT.S14153829180878
   PubMed Web of Science ®Google Scholar
• HuJZhangZZhengROn-treatment markers as predictors to guide anti-EGFR MoAb treatment in metastatic colorectal cancer: a systematic review with meta-analysisCancer Chemother Pharmacol20177927528510.1007/s00280-016-3196-227878357
   PubMed Web of Science ®Google Scholar